Core Insights - The forum highlighted the latest advancements in aesthetic medicine, focusing on trends and technologies in the Asian market [1] Group 1: Key Achievements - Launch of the ReNature aesthetic system, which emphasizes three styles: "youthful, intelligent, and original," and utilizes the "HOOD" four-dimensional analysis method to promote natural and personalized beauty [2] - Introduction of the V-Line chin support technology, designed to address common issues in Asian facial structures, enhancing side profile contours [2] - Release of the high-end filler material "Funiwei·Zhiya Pro," a new generation hyaluronic acid product known for its high cohesiveness, strong support, and safety [2] Group 2: Academic Contributions - Presentation by Professor Wu Suofan on the anatomical basis and scientific rationale behind the ReNature system [3] - Speech by Liow Tiong Sin on the importance of V-Line chin support in Asian facial aesthetics [3] - Dr. Ma Yao's interpretation of the ReNature aesthetic strategy, showcasing clinical applications through case studies [3] Group 3: Strategic Developments - Announcement of the enhancement of the "Micro-Beauty Expert Team," comprising experienced doctors in facial sculpting and aesthetic treatments [3] - The forum aimed to establish an international academic exchange platform in the aesthetic medicine field, supported by participation from numerous experts [3]

最近三个交易日，21日-25日，朗姿股份分别获融资买入0.46亿元、0.30亿元、0.27亿元。 融券方面，当日融券卖出2.32万股，净卖出2.32万股。 8月25日，沪深两融数据显示，朗姿股份获融资买入额0.27亿元，居两市第2290位，当日融资偿还额0.23 亿元，净买入450.79万元。 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The retail industry is experiencing a recovery, with high growth in premium and fashionable segments, particularly in gold jewelry and beauty care [23][27] - The report emphasizes the importance of emotional consumption themes driving growth in high-quality companies within the sector [30] Summary by Sections Retail Market Review - The retail industry index rose by 4.21% during the week of August 18-22, 2025, outperforming the Shanghai Composite Index by 2.20 percentage points [12][20] - The internet e-commerce sector showed the highest growth, with a weekly increase of 7.71% [13][17] - Year-to-date, the jewelry sector has led with a 33.74% increase [13][17] Retail Insights: Mid-Year Reports - Gold jewelry companies like Laopuhuang and Chaohongji reported significant revenue growth, with Laopuhuang achieving a revenue of 12.354 billion yuan (+251.0%) and a net profit of 2.268 billion yuan (+285.8%) [23][35] - Beauty care brands such as Shanghai Jahwa and Runben also showed positive performance, with Shanghai Jahwa reporting a net profit of 266 million yuan (+11.7%) [27][38] Focus on High-Quality Companies - Investment focus includes: - Gold jewelry brands with differentiated product offerings, recommending Laopuhuang and Chaohongji [30][32] - Offline retail companies adapting to trends, recommending Yonghui Supermarket and Aiyingshi [30][32] - High-quality domestic beauty brands, recommending Maogeping and Pola [30][32] - Medical beauty product manufacturers, recommending Aimeike and Kedi-B [30][32] Company-Specific Highlights - Laopuhuang: Achieved a revenue of 12.354 billion yuan (+250.9%) and a net profit of 2.268 billion yuan (+285.8%) in H1 2025, with strong brand expansion and channel upgrades [35][36] - Runben: Reported a revenue of 895 million yuan (+20.3%) and a net profit of 188 million yuan (+4.2%) in H1 2025, focusing on expanding its product matrix [38][40] - Aiyingshi: Achieved a revenue of 1.835 billion yuan (+8.3%) and a net profit of 46.74 million yuan (+10.2%) in H1 2025, with steady store expansion [42]

Group 1 - The core viewpoint of the article highlights the fluctuating investment and financing trends in China's medical beauty industry, with a peak in 2016 and a decline thereafter [1][17] - Investment events peaked in 2016 with 19 occurrences and an investment amount of 1.353 billion RMB, while the highest investment amount was recorded in 2018 at 2.374 billion RMB [1] - By 2024, only 3 investment events occurred with a total investment of 150 million RMB, and as of June 5, 2025, only 1 event with an investment of 30 million RMB was reported [1] Group 2 - The majority of investment rounds in the medical beauty industry are concentrated in early stages, particularly angel and A-round financing [2] - The industry encompasses various fields such as medical beauty raw materials, equipment, and service platforms, indicating strong innovation and technical barriers [2] Group 3 - Investment activities are primarily concentrated in Beijing and Guangdong, with 49 and 23 financing events respectively, followed by Sichuan and Shanghai with 12 and 9 events [4] - The focus on these regions is attributed to the concentration of resources and opportunities in the medical beauty sector [4] Group 4 - The investment direction is primarily focused on the construction of medical beauty platforms [6] Group 5 - The main investment entities in the medical beauty industry are capital organizations, accounting for 73% of the total, while industrial entities like Gree Electric and Xiaomi Group make up 27% [5] Group 6 - There are few industry investment funds specifically targeting medical beauty, with only 2 private funds identified [13] Group 7 - Recent years have seen a trend of horizontal acquisitions among midstream enterprises in the medical beauty industry as a means to expand scale [15] - Notable acquisition events include 康哲药业 acquiring 旭俐医疗 with a 100% stake and 新氧 acquiring 奇致激光 [16] Group 8 - Overall, the investment and financing landscape in China's medical beauty industry has shown fluctuations, with a concentration of activities in Beijing and Guangdong, primarily driven by capital investment institutions [17]

Core Viewpoint - Langzi Co., Ltd. has approved a guarantee for its wholly-owned subsidiary, Sichuan Jingfu Medical Beauty Hospital, to secure a loan of 10 million yuan from China Bank, with a total external guarantee limit set at 3.05 billion yuan for 2025 [2][5]. Summary by Sections Guarantee Overview - The total external guarantee limit for Langzi Co. and its subsidiaries for 2025 is capped at 3.05 billion yuan, with 2.4 billion yuan allocated for subsidiaries with a debt-to-asset ratio below 70% and 650 million yuan for those above [2]. - As of the announcement date, the total external guarantee balance is 1.09216 billion yuan, representing 39.18% of the company's audited net assets for 2024 [2][7]. Details of the Guaranteed Party - Sichuan Jingfu Medical Beauty Hospital, wholly owned by Langzi Co., has a registered capital of 20 million yuan and was established on April 30, 2005 [6][7]. - The hospital is not listed as a dishonest executor [7]. Guarantee Agreement Main Points - The guarantee is a joint liability guarantee for a loan of 10 million yuan, with a guarantee period of three years from the debt performance deadline [7]. - The guarantee covers principal, interest, penalties, and other related costs [7]. Board of Directors' Opinion - The board believes that providing this guarantee will support the subsidiary's business development and will not negatively impact the company's operations or shareholder interests [7]. Cumulative External Guarantee Amount - The cumulative external guarantee amount for the company and its subsidiaries is 1.828 billion yuan, with no overdue guarantees or litigation-related guarantees reported [8].

（文章来源：证券日报） 证券日报网讯 8月22日晚间，朗姿股份发布公告称，截至本公告披露日，公司及控股子公司的担保额度 总金额为182，800万元，对外担保总余额为109，216万元（此处总金额与总余额的统计为剔除多方担保 时重复计算的金额），占公司2024年度经审计净资产的39.18%。公司及控股子公司无逾期对外担保、 无涉及诉讼的对外担保及因担保被判决败诉而应承担损失的情形。 ...

南财智讯8月22日电，朗姿股份公告，为全资子公司四川晶肤医学美容医院有限公司提供1000万元人民 币的连带责任保证，用于其向中国银行申请借款。此担保已获公司第五届董事会第二十九次会议和2024 年度股东大会审议通过，并在2025年度对外担保额度内。截至公告日，公司及控股子公司对外担保总余 额为109216万元，占2024年度经审计净资产的39.18%。公司及控股子公司无逾期担保、无涉及诉讼的 对外担保及因担保被判决败诉而应承担损失的情况。 ...

（记者 曾健辉） 每经头条（nbdtoutiao）——核心产品净值仅剩7毛钱，昔日"公募一哥"任泽松怎么了？牛市踏空真相曝 光 每经AI快讯，朗姿股份8月22日晚间发布公告称，截至本公告披露日，公司及控股子公司的担保额度总 金额为18.28亿元，对外担保总余额约为10.92亿元，占公司2024年度经审计净资产的39.18%；其中，实 际被担保方北京莱茵服装有限公司资产负债率超过70%，公司对资产负债率超过70%的控股子公司担保 余额为1000万元。公司及其控股子公司对合并报表外单位提供的担保总余额为3.6亿元，占公司2024年 度经审计净资产的12.92%。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002612 证券简称：朗姿股份 公告编号：2025-048 朗姿股份有限公司 关于为全资子公司提供担保的公告 特别提示： 1、朗姿股份有限公司（以下简称"朗姿股份"或"公司"）第五届董事会 第二十九次会议和 2024 年度股东大会分别审议通过了《关于 2025 年度对外担保 额度的议案》，同意 2025 年度公司及其控股子公司的对外担保总额不超过 30.50 亿元（以下除非特别注明，所称"元"均指"人民币元"），其中对资产负债率 未超过 70%的控股子公司担保额度为 24.00 亿元，对资产负债率超过 70%的控股 子公司担保额度为 6.50 亿元。该担保额度的有效期自公司 2024 年度股东大会审 议批准本议案之日起至 2025 年度股东大会召开之日止。截止本公告披露日，公 司及控股子公司对外担保总余额为 109,216 万元，占公司 2024 年度经审计净资 产的 39.18%；其中，实际被担保方北京莱茵服装有限公司资产负债率超过 70%， 公司对资产负债率超过 70%的控股子公司担保余额为 1, ...

证券代码：003010 证券简称：若羽臣 公告编号：2025-081 一、权益变动情况 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 朗姿股份有限公司不属于公司控股股东、实际控制人，本次权益变动不会对公司治理结 构、股权结构及未来持续经营产生重大影响，也不会导致公司控制权发生变更。 广州若羽臣科技股份有限公司（以下简称"公司"、"若羽臣"）于2025年6月9日披露 了《关于持股5%以上股东减持股份预披露公告》（公告编号：2025-052），朗姿股份有限公 司（以下简称"朗姿股份"）计划合计减持若羽臣股份数量不超过4,768,071股，不超过若 羽臣总股本的3%。其中，通过集中竞价方式减持不超过1,589,357股，不超过若羽臣总股本 的1%，且在任意连续90个自然日内减持股份的总数不超过若羽臣总股本的1%；通过大宗交易 方式减持不超过3,178,714股，不超过若羽臣总股本的2%，且任意连续90个自然日内减持股 份的总数不超过若羽臣总股本的2%。（总股本以公司当时总股本164,030,506股剔除公司截 至当时已披露回购结果的2024年第三期股份回购和2024年第四期股份 ...